XTL Financial Statements From 2010 to 2024

XTLB Stock  USD 1.88  0.05  2.73%   
XTL Biopharmaceutica financial statements provide useful quarterly and yearly information to potential XTL Biopharmaceuticals Ltd investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on XTL Biopharmaceutica financial statements helps investors assess XTL Biopharmaceutica's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting XTL Biopharmaceutica's valuation are summarized below:
Quarterly Earnings Growth
(0.76)
Market Capitalization
10.2 M
Earnings Share
(0.03)
We have found one hundred twenty available fundamental gauges for XTL Biopharmaceuticals, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XTL Biopharmaceuticals prevalent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself for the next two years. The current year's Market Cap is expected to grow to about 5.4 M. The current year's Enterprise Value is expected to grow to about 3.9 M

XTL Biopharmaceutica Total Revenue

0.0

Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 726.8 K, Research Development of 29.4 K or Total Operating Expenses of 726.8 K, as well as many indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0 or PTB Ratio of 2.41. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
  
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.

XTL Biopharmaceutica Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.3 M2.4 M9.1 M
Slightly volatile
Total Stockholder Equity2.1 M2.2 MM
Slightly volatile
Common Stock Shares Outstanding572.2 M544.9 M77.7 M
Slightly volatile
Liabilities And Stockholders Equity2.3 M2.4 M9.1 M
Slightly volatile
Other Stockholder Equity148.3 M168.3 M140.8 M
Slightly volatile
Total Liabilities195.7 K206 K967.4 K
Slightly volatile
Other Current Liabilities194.8 K205 K420.6 K
Slightly volatile
Total Current Liabilities195.7 K206 K678.2 K
Slightly volatile
Other Liabilities1.3 M1.2 M1.4 M
Pretty Stable
Accounts Payable9501000323.5 K
Slightly volatile
Cash1.3 M1.4 M2.6 M
Very volatile
Non Current Assets Total324.9 K342 K1.5 M
Slightly volatile
Cash And Short Term Investments1.9 MM5.3 M
Slightly volatile
Net Receivables27.6 K29 K122.1 K
Slightly volatile
Common Stock Total Equity15.9 M15.2 M9.8 M
Slightly volatile
Short Term Investments574.8 K605 K2.7 M
Slightly volatile
Other Current Assets10.4 K11 K74.8 K
Pretty Stable
Property Plant And Equipment Gross1.7 K1.8 K72 K
Slightly volatile
Total Current Assets1.9 MM5.6 M
Slightly volatile
Common Stock17 M16.2 M10.1 M
Slightly volatile
Property Plant Equipment85590085 K
Slightly volatile
Intangible Assets324.9 K342 K968.7 K
Slightly volatile
Current Deferred Revenue29.9 K31.5 K58.7 K
Slightly volatile
Short Term DebtM578.7 K749.2 K
Slightly volatile
Short and Long Term Debt Total904.6 K952.2 K1.2 M
Slightly volatile
Net Tangible Assets4.6 M4.2 MM
Slightly volatile
Capital Surpluse119 M132.9 M145.3 M
Slightly volatile
Net Invested Capital4.2 M2.2 M4.4 M
Pretty Stable
Net Working Capital1.7 M1.8 M5.4 M
Slightly volatile
Capital Stock15 M16.2 M13.6 M
Slightly volatile

XTL Biopharmaceutica Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses726.8 K765 K2.5 M
Slightly volatile
Research Development29.4 K31 K866.5 K
Slightly volatile
Total Operating Expenses726.8 K765 K2.5 M
Slightly volatile
Depreciation And Amortization85590097.1 K
Slightly volatile
Selling General Administrative697.3 K734 K2.1 M
Slightly volatile
Selling And Marketing Expenses920.8 K843.3 K737 K
Pretty Stable
Non Recurring1.1 M763.2 K1.2 M
Slightly volatile

XTL Biopharmaceutica Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.9 M2.1 M2.5 M
Slightly volatile
End Period Cash Flow1.3 M1.4 M2.6 M
Very volatile
Sale Purchase Of Stock3.2 M5.6 M3.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.150.160.2536
Slightly volatile
PTB Ratio2.412.29630.3482
Slightly volatile
Days Sales Outstanding21.2122.3328.3633
Slightly volatile
Book Value Per Share0.00390.00410.1797
Slightly volatile
Capex To Depreciation8.918.496.282
Slightly volatile
PB Ratio2.412.29630.3482
Slightly volatile
Inventory Turnover0.00.00.3974
Slightly volatile
Days Of Inventory On Hand18.1 M17.2 M13.8 M
Slightly volatile
Payables Turnover1.0E-41.0E-40.2356
Slightly volatile
Sales General And Administrative To Revenue1.680.961.1736
Slightly volatile
Research And Ddevelopement To Revenue0.05210.05490.3
Slightly volatile
Capex To Revenue0.03540.03190.0438
Slightly volatile
Cash Per Share0.00350.00370.0762
Slightly volatile
Days Payables Outstanding4.4 M4.2 M3.4 M
Slightly volatile
Intangibles To Total Assets0.180.15660.1481
Pretty Stable
Current Ratio7.989.93213.4204
Slightly volatile
Tangible Book Value Per Share0.00320.00340.176
Slightly volatile
Receivables Turnover17.7716.9216.1109
Slightly volatile
Graham Number5.0E-45.0E-40.4019
Slightly volatile
Shareholders Equity Per Share0.00390.00410.1695
Slightly volatile
Capex Per Share0.00.03.0E-4
Slightly volatile
Revenue Per Share0.01160.01220.0178
Slightly volatile
Interest Debt Per Share1.0E-41.0E-41.0E-4
Slightly volatile
Price Book Value Ratio2.412.29630.3482
Slightly volatile
Days Of Payables Outstanding4.4 M4.2 M3.4 M
Slightly volatile
Company Equity Multiplier1.041.09281.1882
Slightly volatile
Quick Ratio7.899.93213.2819
Slightly volatile
Net Income Per E B T0.00110.00120.3771
Slightly volatile
Cash Ratio4.746.8017.6607
Slightly volatile
Days Of Inventory Outstanding18.1 M17.2 M13.8 M
Slightly volatile
Days Of Sales Outstanding21.2122.3328.3633
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9941
Slightly volatile
Price To Book Ratio2.412.29630.3482
Slightly volatile
Fixed Asset Turnover24.4834.9531.8433
Slightly volatile
Price Sales Ratio0.150.160.2536
Slightly volatile
Asset Turnover0.290.270.2546
Slightly volatile
Gross Profit Margin0.430.620.6104
Slightly volatile
Price Fair Value2.412.29630.3482
Slightly volatile
Operating Cycle144151174
Slightly volatile

XTL Biopharmaceutica Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.4 M5.1 M949.5 K
Slightly volatile

XTL Fundamental Market Drivers

Cash And Short Term InvestmentsM

XTL Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About XTL Biopharmaceutica Financial Statements

XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue31.5 K29.9 K
Cost Of Revenue 900.00  855.00 
Stock Based Compensation To Revenue(0.03)(0.03)
Sales General And Administrative To Revenue 0.96  1.68 
Research And Ddevelopement To Revenue 0.05  0.05 
Capex To Revenue 0.03  0.04 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(1.10)(1.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.03)
Return On Assets
(0.14)
Return On Equity
(0.13)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.